Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, Against Triple-Negative Breast and Gastric Cancers

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0132
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combining Anti-Ctla4 With RG7787, an Immunotoxin Targeting Mesothelin, Promotes Tumor Eradication

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Molecular Stratification of Triple-Negative Breast Cancers

Oncologist
Cancer ResearchMedicineOncology
2010English

Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

BRCA1/2-negative Hereditary Triple-Negative Breast Cancers Exhibit BRCAness

International Journal of Cancer
Cancer ResearchOncology
2017English

Transgelin: A Potentially Useful Diagnostic Marker Differentially Expressed in Triple-Negative and Non–triple-Negative Breast Cancers

Human Pathology
Forensic MedicinePathology
2015English

Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future

Women's Health
Medicine
2015English

Profiling Molecular Regulators of Recurrence in Chemorefractory Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2019English

The Efficacy of Betulinic Acid in Triple-Negative Breast Cancer

SAGE Open Medicine
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy